HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights.
“The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “New data announcements on our REYOBIQ™ CNS cancer radiotherapeutic clinical trials continue to demonstrate favorable safety and efficacy signals, facilitating active enrollment on our dose optimization trial. Furthermore, the recently announced launch of the CNSide® cerebral spinal fluid (CSF) assay platform and testing services in Texas with initial focus on national cancer centers validates the clinical need for our diagnostic management tool. We intend to expand our testing services and broaden the regional availability of CNSide over the next 12 months.”
Q2 2025 & RECENT HIGHLIGHTS AND MILESTONES
Corporate
REYOBIQ™ Clinical Trials
CNSide CSF Assay Platform
1 The Company has derived this number based on published CNS cancer incidence data, third-party projections of test utilization, and established market benchmarks
Q2 2025 FINANCIAL RESULTS
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in LM and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
About REYOBIQ (rhenium 186re obisbemeda)
REYOBIQ (rhenium 186re obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide in the U.S. in 2025.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements regarding the potential promise of REYOBIQ, expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of REYOBIQ™ including through evaluations in additional patient cohorts; and expectations regarding receipt of grant funds.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company’s ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company’s common stock on Nasdaq; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
CORE IR
This email address is being protected from spambots. You need JavaScript enabled to view it.
| PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and par value data) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,233 | $ | 76 | ||||
| Investments | 4,646 | 3,530 | ||||||
| Grant receivable | 1,021 | 571 | ||||||
| Other current assets | 1,314 | 1,082 | ||||||
| Total current assets | 9,214 | 5,259 | ||||||
| Property and equipment, net | 289 | 448 | ||||||
| Operating lease right-use-of assets | 29 | 73 | ||||||
| Goodwill | 372 | 372 | ||||||
| Intangible assets, net | 401 | 469 | ||||||
| Other assets | 45 | 12 | ||||||
| Total assets | $ | 10,350 | $ | 6,633 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 6,359 | $ | 11,288 | ||||
| Operating lease liability | 30 | 44 | ||||||
| Deferred grant liability | 927 | 927 | ||||||
| Line of credit | — | 3,292 | ||||||
| Total current liabilities | 7,316 | 15,551 | ||||||
| Noncurrent operating lease liability | — | 31 | ||||||
| Total liabilities | 7,316 | 15,582 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | — | ||||||
| Common stock, $0.001 par value; 2,000,000,000 shares authorized; 92,438,432 shares issued; and 92,180,007 shares outstanding as of June 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively | 92 | 6 | ||||||
| Treasury stock (at cost), 258,425 shares as of June 30, 2025 and December 31, 2024, respectively | (500 | ) | (500 | ) | ||||
| Additional paid-in capital | 509,171 | 485,024 | ||||||
| Accumulated deficit | (505,729 | ) | (493,479 | ) | ||||
| Total stockholders’ equity (deficit) | 3,034 | (8,949 | ) | |||||
| Total liabilities and stockholders’ equity | $ | 10,350 | $ | 6,633 | ||||
| PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Grant revenue | $ | 1,390 | $ | 1,279 | $ | 2,449 | $ | 2,956 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,246 | 2,773 | 3,002 | 5,536 | ||||||||||||
| General and administrative | 1,682 | 2,203 | 4,521 | 4,416 | ||||||||||||
| Total operating expenses | 2,928 | 4,976 | 7,523 | 9,952 | ||||||||||||
| Operating loss | (1,538 | ) | (3,697 | ) | (5,074 | ) | (6,996 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 27 | 67 | 28 | 139 | ||||||||||||
| Interest expense | — | (27 | ) | (548 | ) | (61 | ) | |||||||||
| Financing expenses | 150 | (3,545 | ) | (3,061 | ) | (3,545 | ) | |||||||||
| Warrant issuance costs | — | (432 | ) | (964 | ) | (432 | ) | |||||||||
| Change in fair value of derivative instruments | 6,512 | 4,694 | (2,631 | ) | 4,694 | |||||||||||
| Total other income (expense) | 6,689 | 757 | (7,176 | ) | 795 | |||||||||||
| Net income (loss) | $ | 5,151 | $ | (2,940 | ) | $ | (12,250 | ) | $ | (6,201 | ) | |||||
| Per share information | ||||||||||||||||
| Net income (loss) per share of common stock – basic | $ | 0.02 | $ | (0.45 | ) | $ | (0.50 | ) | $ | (1.15 | ) | |||||
| Weighted average number of shares of common stock outstanding – basic | 48,388,862 | 6,500,831 | 24,422,125 | 5,411,382 | ||||||||||||
| Net loss per share of common stock – diluted | $ | (0.01 | ) | $ | (0.71 | ) | $ | (0.50 | ) | $ | (1.45 | ) | ||||
| Weighted average number of shares of common stock outstanding – diluted | 209,154,994 | 10,742,924 | 24,422,125 | 7,532,428 | ||||||||||||
| PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (In thousands) | ||||||||
| For the Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows used in operating activities: | ||||||||
| Net loss | $ | (12,250 | ) | $ | (6,201 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 223 | 325 | ||||||
| Amortization of deferred financing costs and debt discount | — | 20 | ||||||
| Share-based compensation expense | 300 | 297 | ||||||
| Noncash financing expenses | 3,061 | 3,545 | ||||||
| Change in fair value of derivative instruments | 2,631 | (4,694 | ) | |||||
| Accretion of discount on short-term investments | (22 | ) | (23 | ) | ||||
| Reduction in the carrying amount of operating lease right-of-use assets | 44 | 63 | ||||||
| Gain on sale of assets | (16 | ) | — | |||||
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||||||||
| Grant receivable | (450 | ) | — | |||||
| Other current assets | (265 | ) | 335 | |||||
| Accounts payable and accrued expenses | (5,181 | ) | 360 | |||||
| Change in operating lease liabilities | (45 | ) | (63 | ) | ||||
| Deferred grant liability | — | 373 | ||||||
| Net cash used in operating activities | (11,970 | ) | (5,663 | ) | ||||
| Cash flows used in investing activities: | ||||||||
| Purchases of property and equipment | (10 | ) | (121 | ) | ||||
| Purchase of short-term investments | (7,756 | ) | (3,500 | ) | ||||
| Redemption of short-term investments | 6,662 | — | ||||||
| Purchase of intangible assets | — | (545 | ) | |||||
| Proceeds from sale of property and equipment | 30 | — | ||||||
| Net cash used in investing activities | (1,074 | ) | (4,166 | ) | ||||
| Cash flows provided by financing activities: | ||||||||
| Principal payments of term loan obligation | — | (3,996 | ) | |||||
| Proceeds from credit facility | — | 3,292 | ||||||
| Repayment of line of credit facility | (3,292 | ) | — | |||||
| Repayment of notes payable | (3,703 | ) | — | |||||
| Issuance of notes payable and warrants | 3,738 | — | ||||||
| Proceeds from exercise of Series B Warrants from May 2024 PIPE | 882 | — | ||||||
| Purchase of treasury stock | — | (374 | ) | |||||
| Proceeds from sale of common stock, pre-funded warrants and warrants | 15,001 | 7,310 | ||||||
| Proceeds from sale of common stock under Lincoln Park Purchase Agreement | 2,795 | — | ||||||
| Costs from sale of common stock | (220 | ) | (45 | ) | ||||
| Net cash provided by financing activities | 15,201 | 6,187 | ||||||
| Net increase (decrease) in cash and cash equivalents | 2,157 | (3,642 | ) | |||||
| Cash and cash equivalents at beginning of period | 76 | 8,554 | ||||||
| Cash and cash equivalents at end of period | $ | 2,233 | $ | 4,912 | ||||
| Supplemental disclosure of cash flows information: | ||||||||
| Cash paid during period for: | ||||||||
| Interest | $ | 539 | $ | 32 | ||||
| Supplemental schedule of non-cash investing and financing activities: | ||||||||
| Exchange of warrants for notes payable | $ | 3,694 | $ | — | ||||
| Redemption of notes by issuance of common stock, pre-funded warrants and warrants | $ | 3,512 | $ | — | ||||
| Unpaid offering cost | $ | 252 | $ | 375 | ||||
| Last Trade: | US$0.63 |
| Daily Change: | 0.08 15.27 |
| Daily Volume: | 12,830,256 |
| Market Cap: | US$37.810M |
August 14, 2025 July 15, 2025 July 10, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
